SCHEMBL19785654

SCHEMBL19785654

C=CCSS/C=C\C[S+]([O-])Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12362844 1.00 PTGS2 (0.36) PTGS2
SCHEMBL12362845 0.86 PTGS2 (0.35) PTGS2
SCHEMBL19786145 0.84 MAOB (0.34)
SCHEMBL23855349 0.84 MAOB (0.34)
SCHEMBL21189909 0.84 MAOB (0.34)
SCHEMBL23796922 0.83 PTGS2 (0.33) PTGS2
SCHEMBL1841062 0.83 TP53 (0.41) PTGS2
SCHEMBL23797015 0.83 PTGS2 (0.33) PTGS2
SCHEMBL1841064 0.83 TP53 (0.41) PTGS2
SCHEMBL21177503 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-01-25 US disclosed
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-01-25 US disclosed
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2021-09-30 US disclosed
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2021-09-30 US disclosed
WO-2019143143-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROBLASTOMA OR RHEUMATOID ARTHRITIS 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
WO-2019143142-A1 NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
WO-2018012947-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT 숙명여자대학교 산학협력단 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient HDAC1, HDAC2, HDAC11 PTGS2 638/4885
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT HDAC1, HDAC2, HDAC11 PTGS2 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.